



21 November 2024

DorsaVi Commences Blockchain Integration Planning for Core Data Platform to Enhance Data Security and Compliance – Supplementary Information

dorsaVi (ASX: DVL) (“**dorsaVi**” or the “**Company**”), a leader in FDA-cleared wearable sensor technology and motion analysis solutions, provides the below supplementary information following the Company’s announcement of 20 November 2024 titled “DorsaVi Commences Blockchain Integration Planning for Core Data Platform to Enhance Data Security and Compliance” (**Announcement**):

- The incorporation of the blockchain technology to the Company’s core data platform (**Initiative**) aims to improve alignment with stringent health data regulations such as HIPAA¹, reinforcing **dorsaVi**’s leadership in data integrity, privacy, and security, and aims to reduce **DorsaVi**’s current sales cycle with large, security-conscious organisations.
- The Initiative reflects a material opportunity to address the growing data security and privacy requirements of its largest enterprise clients who are already working with the sensitive health and biomechanical data generated by **dorsaVi**’s best-in-class wearable devices and software as well as open new commercialisation opportunities for the Company to engage with other large potential enterprise clients with strict data security requirements.
- Enterprise clients are more likely to move forward quickly when they can trust the integrity and privacy of the data, which is especially important in the healthcare sector. Notably, **Dorsavi** has previously secured sales and pilot programs with large organizations all of which have stringent data security requirements.
- The scoping and feasibility study is expected to conclude by the end of Q1 CY2025 and deliver a clear roadmap for implementation and commercialisation requirements.
- While the cost of the scoping study are not material, its potential outcomes—enhanced engagement with enterprise clients, improved competitive positioning, and access to new regulated markets—represent strategic positioning that could significantly influence **dorsaVi**’s future prospects and market value.
- The ability to offer a secure, tamper-proof solution aligns with the priorities of clients in highly regulated industries and could significantly enhance **dorsaVi**’s engagement with these security-conscious organisations to deliver value to enterprise customers and unlocking new commercial opportunities.

This release has been authorised for lodgement by the Company’s Board of Directors.

- ENDS -

¹ HIPAA = Health Insurance Portability and Accountability Act. A US federal law designed to protect sensitive patient health information from being disclosed without the patient’s consent or knowledge.

For personal use only

For further information about dorsaVi, please contact:

Andrew Ronchi
Chief Executive Officer
+61 417 882 267
Email: ar@dorsaVi.com

About dorsaVi

dorsaVi Ltd (ASX: DVL) is an ASX company focused on developing innovative motion analysis device technologies for use in clinical applications, elite sports, and occupational health and safety. dorsaVi believes its wearable sensor technology enables, for the first time, many aspects of detailed human movement and position to be accurately captured, quantified, and assessed outside a biomechanics lab, in both real-time and real situations for up to 24 hours. dorsaVi's focus is on two major markets:

- **Workplace:** dorsaVi enables employers to assess risk of injury for employees as well as test the effectiveness of proposed changes to OHS workplace design, equipment or methods based on objective evidence. dorsaVi works either directly with major corporations, or through an insurance company's customer base with the aim of reducing workplace compensation and claims. dorsaVi has been used by major corporations including London Underground, Vinci Construction, Crown Resorts, Caterpillar (US), Boeing, Monash Health, Coles, Woolworths, Toll, Toyota, Orora, Mineral Resources and BHP Billiton.
- **Clinical:** dorsaVi is transforming the management of patients with its clinical solutions (ViMove+) which provide objective assessment, monitoring outside the clinic and immediate biofeedback. The clinical market is broken down into physical therapy (physiotherapists), hospital in the home and elite sports. Hospital in the home refers to the remote management of patients by clinicians outside of physical therapy (i.e. for orthopaedic conditions). Elite sports refer to the management and optimisation of athletes through objective evidence for decisions on return to play, measurement of biomechanics and immediate biofeedback to enable peak performance.

Further information is available at www.dorsaVi.com